Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies

Burgos-Vargas, 2013, Current therapies in rheumatoid arthritis: a Latin American perspective, Reumatol Clin, 9, 106, 10.1016/j.reuma.2012.09.001 Machado-Alba, 2015, The epidemiology of rheumatoid arthritis in a cohort of Colombian patients, Rev Colomb Reumatol, 22, 148 Anaya, 2001, Rheumatoid arthritis in African Colombians from Quibdo, Semin Arthritis Rheum, 31, 191, 10.1053/sarh.2001.27737 Díaz-Rojas, 2016, Prevalencia de artritis reumatoide en Colombia: una aproximación basada en la carga de la enfermedad durante el año 2005, Rev Colomb Reumatol, 23, 11 Smolen, 2017, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis, 76, 960, 10.1136/annrheumdis-2016-210715 Singh, 2016, 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol, 68, 1, 10.1002/art.39480 Cardiel, 2006, First Latin American position paper on the pharmacological treatment of rheumatoid arthritis, Rheumatology (Oxford), 45, ii7 Cardiel, 2012, Treating rheumatoid arthritis in Latin America: current challenges and future treatment strategies, Int J Clin Rheumatol, 7, 139, 10.2217/ijr.12.6 Cardiel, 2012, Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience, J Clin Rheumatol, 18, 327, 10.1097/RHU.0b013e31826d6610 Mody, 2008, Challenges in the management of rheumatoid arthritis in developing countries, Best Pract Res Clin Rheumatol, 22, 621, 10.1016/j.berh.2008.04.003 Finckh, 2006, Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis, Arthritis Rheum, 55, 864, 10.1002/art.22353 Caballero Uribe, 2002, Tratamiento de la artritis reumatoide en Colombia. Applicación práctica de los conceptos teóricos por parte de los reumatólogos colombianos, Rev Colomb Reumatol, 9, 242 Bautista-Molano, 2016, Epidemiological profile of Colombian patients with rheumatoid arthritis in a specialized care clinic, Reumatol Clin, 12, 313, 10.1016/j.reuma.2015.11.009 Londoño, 2001, Recomendaciones del comité de expertos de la Asociación Colombiana de Rheumatología para el empleo de terapia bloqueadora del factor de necrosis tumoral en artritis reumatoide, Rev Colomb Reumatol, 8, 296 Machado-Alba, 2016, Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia, Int J Clin Pract, 70, 506, 10.1111/ijcp.12809 Universidad Nacional de Colombia, 2014 World Health Organization, 2016 Londono, 2005, Efficacy and safety of 40 mg adalimumab twice per month in Colombian patients with rheumatoid arthritis (RA) with failure of conventional treatment. An open study in a group of unselected patients “Real life study”, Ann Rheum Dis, 64, 475 Londoño, 2009, Cambio en la capacidad funcional, calidad de vida y actividad de la enfermedad, en un grupo de pacientes colombianos con artritis reumatoide refractaria al tratamiento convencional, que recibieron terapia con Infliximab como medicamento de rescate, Rev Med, 17, 40 Kay, 2014, Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year, Arthritis Res Ther, 16, R40, 10.1186/ar4469 Anderson, 2011, Arthritis Care Res (Hoboken), 63, S14, 10.1002/acr.20621 Munoz, 2017, Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis, Clin Rheumatol, 36, 1143, 10.1007/s10067-016-3521-5 Fleischmann, 2012, Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs, Arthritis Rheum, 64, 617, 10.1002/art.33383 Kremer, 2012, A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone, Arthritis Rheum, 64, 970, 10.1002/art.33419 Kremer, 2009, The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo, Arthritis Rheum, 60, 1895, 10.1002/art.24567 McInnes, 2014, Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study, Ann Rheum Dis, 73, 124, 10.1136/annrheumdis-2012-202442 Tanaka, 2011, Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate, Arthritis Care Res (Hoboken), 63, 1150, 10.1002/acr.20494 Tanaka, 2015, Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study, Mod Rheumatol, 25, 514, 10.3109/14397595.2014.995875 Fleischmann, 2012, Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis, N Engl J Med, 367, 495, 10.1056/NEJMoa1109071 Kremer, 2013, Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial, Ann Intern Med, 159, 253, 10.7326/0003-4819-159-4-201308200-00006 van der Heijde, 2013, Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study, Arthritis Rheum, 65, 559, 10.1002/art.37816 van Vollenhoven, 2012, Tofacitinib or adalimumab versus placebo in rheumatoid arthritis, N Engl J Med, 367, 508, 10.1056/NEJMoa1112072 Lee, 2014, Tofacitinib versus methotrexate in rheumatoid arthritis, N Engl J Med, 370, 2377, 10.1056/NEJMoa1310476 Burmester, 2013, Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial, Lancet, 381, 451, 10.1016/S0140-6736(12)61424-X Wollenhaupt, 2014, Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies, J Rheumatol, 41, 837, 10.3899/jrheum.130683 Yamanaka, 2016, Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study, Arthritis Res Ther, 18, 34, 10.1186/s13075-016-0932-2 Wollenhaupt, 2017, Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years, Arthritis Rheumatol, 69, 683 Radominski, 2016, Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of Phase 3 and long-term extension studies, Reumatol Clin Castañeda, 2017, Safety of tofacitinib in the treatment of rheumatoid arthritis in Latin America compared with the rest of the world population, J Clin Rheumatol, 23, 193, 10.1097/RHU.0000000000000498 Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 da Mota, 2012, 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis, Rev Bras Reumatol, 52, 152 Cardiel, 2014, Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis, Reumatol Clin, 10, 227, 10.1016/j.reuma.2013.10.006 US Food and Drug Administration, 2017 Winthrop, 2016, Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1133, 10.1136/annrheumdis-2015-207319 Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum, 52, 1766, 10.1002/art.21043 Marino, 2007, Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue, PLoS Comput Biol, 3, 1909, 10.1371/journal.pcbi.0030194 Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 529, 10.1136/annrheumdis-2013-204575 FDA, 2012 Titton, 2011, Brazilian biologic registry: biobadaBrasil implementation process and preliminary results, Rev Bras Reumatol, 51, 152, 10.1590/S0482-50042011000200005 Ventura-Rios, 2012, Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0, Reumatol Clin, 8, 189 Wollenhaupt, 2014, Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 6 years, Arthritis Rheumatol, 74, S375 Barreto, 2012, Epidemiology in Latin America and the Caribbean: current situation and challenges, Int J Epidemiol, 41, 557, 10.1093/ije/dys017 Hotez, 2008, The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination, PLoS Negl Trop Dis, 2, e300, 10.1371/journal.pntd.0000300 Velez P, Jaller JJ, Otero W, Persand K, Mahgoub EY, Mebus C, et al. Tofacitinib, an oral Janus kinase inhibitor, in patients from Latin America with rheumatoid arthritis: pooled efficacy and safety analyses. Asociación Colombiana de Rheumatología, Medellín, Colombia, August 15–18, 2013.